Peptide Antibiotics Market Report 2026

The peptide antibiotics market size has grown strongly in recent years. It will grow from $5.77 billion in 2025 to $6.32 billion in 2026 at a compound annual growth rate (CAGR) of 9.6%. The growth in the historic period can be attributed to rise of antibiotic-resistant bacterial strains, increased hospital-acquired infection rates, advancements in peptide synthesis technologies, growing clinical research in infectious diseases, government funding for antibiotic R&D.

The peptide antibiotics market size is expected to see strong growth in the next few years. It will grow to $9.04 billion in 2030 at a compound annual growth rate (CAGR) of 9.3%. The growth in the forecast period can be attributed to rising prevalence of multi-drug resistant infections, expansion of global healthcare infrastructure, technological advancements in peptide delivery systems, increasing collaborations with cdmоs, rising awareness and adoption of precision medicine approaches. Major trends in the forecast period include rising demand for multi-drug resistant (mdr) infection solutions, expansion of peptide antibiotics in hospital-acquired infections, growth of contract manufacturing and cdmo collaborations, increasing adoption of personalized and targeted antibiotic therapies, focus on peptide antibiotics with reduced toxicity and side effects.

The growing prevalence of various infectious diseases is expected to drive the growth of the peptide antibiotics market. Infectious diseases are conditions caused by harmful microorganisms such as bacteria, fungi, parasites, and others. Key factors contributing to the rise in infectious diseases include rapid urbanization, climate change, and an increased risk of disease emergence, among others, which have led to higher demand for peptide antibiotics. Peptide antibiotics exert their antibacterial effects by physically disrupting bacterial cell membranes. For example, in May 2024, according to the World Health Organization, a Switzerland-based intergovernmental organization, dengue cases in the Americas had already exceeded seven million by April 2024, significantly higher than the 4.6 million cases recorded throughout 2023. Therefore, the rising incidence of infectious diseases is contributing to the growth of the peptide antibiotics market.

A rise in the prevalence of chronic diseases is anticipated to drive the growth of the peptide antibiotics market. Chronic diseases are conditions that persist for a year or longer, require continuous medical management, and restrict daily activities. The growing burden of chronic illnesses is attributed to factors such as increased tobacco use, unhealthy diets, lack of physical activity, excessive alcohol consumption, and other lifestyle-related causes. Peptide antibiotics are utilized in the treatment of chronic diseases by delivering the medication directly to the targeted area. For example, in February 2024, according to the World Health Organization, a Switzerland-based intergovernmental organization, more than 35 million new cancer cases are projected by 2050, representing a 77% increase compared to the estimated 20 million cases in 2022. Hence, the rising prevalence of chronic diseases is contributing to the growth of the peptide antibiotics market.

Major companies operating in the peptide antibiotics market are introducing generic versions to offer more affordable treatment options for patients. Generic peptide antibiotics are lower-cost, off-patent alternatives to branded peptide-based antibiotics and are used to treat a range of bacterial infections. For example, in July 2023, Camber Pharmaceuticals, a US-based pharmaceutical company, expanded its product portfolio by launching a generic version of Daptomycin for Injection. Daptomycin for Injection is a peptide antibiotic classified as a cyclic lipopeptide and is produced through a non-ribosomal synthesis process. The generic formulation is available in 350 mg and 500 mg strengths and is indicated for the treatment of complicated skin and skin structure infections (cSSSI) in adult patients as well as pediatric patients aged 1 to 17 years.

Major companies operating in the peptide antibiotics market are Eli Lilly and Company, GlaxoSmithKline plc, Novartis AG, Pfizer Inc., Merck & Co. Inc., AbbVie Inc., Sandoz International GmbH, Xellia APS, Johnson & Johnson Inc., AstraZeneca PLC, Bayer AG, Bristol-Myers Squibb Company, Lupin Pharmaceuticals Inc., Sun Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Ltd., Torrent Pharmaceuticals Ltd., Wockhardt Ltd., Zydus Lifesciences Limited, Alkem Laboratories Limited, Allecra Therapeutics GmbH, Basilea Pharmaceutica Ltd.

North America was the largest region in the peptide antibiotics market in 2025. The regions covered in the peptide antibiotics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the peptide antibiotics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have impacted the peptide antibiotics market by increasing import costs for raw materials and specialized manufacturing equipment, leading to higher production expenses. The ribosomal and non-ribosomal synthesized peptide antibiotics segments are particularly affected, especially in regions like North America and Europe that rely on global supply chains. While some local manufacturers may benefit from protection against foreign competition, overall, tariffs are creating cost pressures that encourage investments in domestic production and supply chain diversification.

The peptide antibiotics market research report is one of a series of new reports that provides peptide antibiotics market statistics, including peptide antibiotics industry global market size, regional shares, competitors with a peptide antibiotics market share, detailed peptide antibiotics market segments, market trends and opportunities, and any further data you may need to thrive in the peptide antibiotics industry. This peptide antibiotics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Peptide antibiotics are antibiotics composed of peptides, with their antibacterial action primarily driven by the physical disruption of bacterial cell membranes. These antibiotics penetrate bacterial membranes, accumulate inside the cells, and subsequently interfere with essential bacterial functions.

The primary types of peptide antibiotics include ribosomally synthesized peptide antibiotics and non-ribosomally synthesized peptide antibiotics. Ribosomally synthesized peptide antibiotics act by destroying or modifying the drug, altering the drug target, reducing or increasing drug uptake, or replacing a metabolic pathway as the drug’s target. Ribosomally synthesized peptide antibiotics are antimicrobial peptides produced by ribosomes and are generated by nearly all forms of life, ranging from bacteria to plants and animals. Common peptide antibiotic drugs include daptomycin, dalbavancin, telavancin, and others, which are used to treat conditions such as skin infections, hospital-acquired and ventilator-associated bacterial pneumonia (HABP/VABP), bloodstream infections, and other diseases. Peptide antibiotics are utilized and distributed through hospitals, homecare settings, specialty clinics, and other distribution channels.

The peptide antibiotics market consists of sales of oral, intravenous, intramuscular and topical peptide antibiotics. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.